No Data
No Data
This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Could Be Less Than A Year Away From Profitability
We feel now is a pretty good time to analyse ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) business as it appears the company may be on the cusp of a considerable accomplishment. ACADIA Pharmaceutical
Express News | ACADIA Pharmaceuticals Inc : BMO Initiates Coverage With Outperform Rating; Target Price $31
ACADIA Pharmaceuticals Initiated at Outperform by BMO Capital
ACADIA Pharmaceuticals Initiated at Outperform by BMO Capital
BMO Capital Initiates Coverage On ACADIA Pharmaceuticals With Outperform Rating, Announces Price Target of $31
BMO Capital analyst Keith Tapper initiates coverage on ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform rating and announces Price Target of $31.
BMO Capital Initiates ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Announces Target Price $31
BMO Capital analyst Evan Seigerman initiates coverage on $ACADIA Pharmaceuticals(ACAD.US)$ with a buy rating, and sets the target price at $31.According to TipRanks data, the analyst has a success rat